TABLE 3.
Description of adverse events (AEs) and AE‐related drug interruptions.
| Drug/procedure | AEs reported/patients n (%) | Patients with AE‐related interruptions n (%) |
|---|---|---|
| Pyridostigmine | 19/187 (10.2) | 10 (5.3) |
| Prednisone | 65/191 (34.0) | 36 (18.8) |
| Azathioprine | 35/105 (33.3) | 21 (20.0) |
| Mycophenolate mofetil | 25/75 (33.3) | 14 (18.7) |
| Cyclosporine A | 23/47 (48.9) | 10 (21.3) |
| Tacrolimus | 2/17 (11.8) | 2 (11.8) |
| Cyclophosphamide | 3/5 (60.0) | 1 (20.0) |
| Periodic IVIG | 2/6 (33.3) | 2 (33.3) |
| Rituximab | 2/17 (11.8) | 2 (11.8) |
| Periodic plasma exchange | 1/2(50.0) | 1 (50.0) |
Note: For each drug or procedure, total number of patients with AEs, total number of patients treated with the drug and percentage (in parentheses) of treated patients with AEs are shown in the second column. Total number of patients and percentage (in brackets) of patients with AE‐related interruptions are shown in the third column.
Abbreviations: AE, adverse event; IVIG, intravenous immunoglobulins.